International price comparisons of Alzheimer's drugs: A way to close the affordability gap

International Psychogeriatrics

Volumn 21, Issue 6, 2009, Pages 1116-1126

  Suh, Guk Hee ^a   Wimo, Anders ^b   Gauthier, Serge ^c   O'Connor, Daniel ^d   Ikeda, Manabu ^e   Homma, Akira ^f   Dominguez, Jacqueline ^g   Yang, Bong Min ^h  

^a Hallym University   (South Korea)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MCGILL UNIVERSITY   (Canada)

^d MONASH UNIVERSITY   (Australia)

^e KUMAMOTO UNIVERSITY   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^g ST LUKE S MEDICAL CENTER   (Philippines)

^h Seoul National University   (South Korea)

Author keywords

Affordability; Alzheimer's; Availability; Dementia; Drug; Price

Indexed keywords

ALZHEIMER DRUG; DONEPEZIL; GALANTAMINE; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARGENTINA; ARTICLE; AUSTRALIA; BRAZIL; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOMINICAN REPUBLIC; DRUG CAPSULE; DRUG COST; DRUG FORMULATION; DRUG MARKETING; DRUG RELEASE; DRUG UTILIZATION; FRANCE; HEALTH SURVEY; HUMAN; INCOME; INDIA; INTERNATIONAL COOPERATION; JAPAN; LIVER INJURY; MACEDONIA (REPUBLIC); MEXICO; MULTICENTER STUDY; NEW ZEALAND; NIGERIA; PHILIPPINES; PURCHASING; QUALITY CONTROL; SERBIA; SOUTH KOREA; SWITZERLAND; TABLET FORMULATION; TAIWAN; THAILAND; UGANDA; UNITED KINGDOM; UNITED STATES;

AGED; ALZHEIMER DISEASE; CROSS-CULTURAL COMPARISON; DEVELOPING COUNTRIES; DRUG COSTS; ECONOMICS; GALANTAMINE; HUMANS; INCOME; INDANS; INDIA; MEMANTINE; MEXICO; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; UNITED STATES;

EID: 75149150224     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S104161020999086X     Document Type: Article

References (12)

1. Danzon, P. M. and Furukawa, M. F. (2006). Prices and availability of biopharmaceuticals: an international comparison. Health Affairs, 25, 1353-1362.
2. Ferri, C. P. et al. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet, 366, 2112-2117.
3. International Monetary Fund (2008). World Economic and Financial Surveys. Available at http://www.imf.org/external/ pubs/ft/weo/2007/02/weodata/index. aspx (last accessed 22 August 2008).
4. Jorm, A. F., Korten, A. E. and Henderson, A. S. (1987). The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatrica Scandinavica, 76, 465-479.
5. Mendis, S. et al. (2007). The availability and affordability of selected essential medicines for chronic diseases in six lowand middle-income countries. Bulletin of the World Health Organization, 85, 279-289.
6. Murray, C. J. L. and Lopez, A.D. (1996) Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston: Harvard University Press.
7. Steinbrook, R. (2007). Closing the affordability gap for drugs in low-income countries. New England Journal of Medicine, 357, 1996-1999.
8. Wimo, A., Jönsson, L. and Winblad, B. (2007). An estimate of the total worldwide societal costs of dementia in 2005. Alzheimeŕs and Dementia, 3, 81-91.
9. World Health Organization (2000). Core Indicators on Country Pharmaceutical Situation. Geneva: WHO Publications.
10. World Health Organization (2002). The World Health Report 2001 Mental Health: New Understanding, New Hope. Geneva: WHO Publications.
11. World Health Organization/World Trade Organization (2001). Background Paper for the WHO-WTO Secretariat Workshop on Differential Pricing and Financing of Essential Drugs. Available at http://www.wto.org/english/tratop-e/ trips-e/hosbjor-presentations-e/28wilder-e.doc (last accessed 22 August 2008).
12. Yang, B. M., Bae, E. and Kim, J. (2008). Economic evaluation and pharmaceutical reimbursement reform in South Korea's national health insurance. Health Affairs, 27, 179-187.